Plasminogen activator inhibitor (PAI-1) and non-insulin-dependent diabetes in Pima Indians, South Asians and Europeans. Populations at varying risk of NIDDM and coronary artery disease

Thrombosis and Haemostasis

Volumn 75, Issue 6, 1996, Pages 921-927

  Nagi, D K ^a,c   Knowler, W C ^a   Hanson, R L ^a   Ali, V Mohamed ^b   Yudkin, J S ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; PROINSULIN; SULFONYLUREA;

ADULT; AGED; AMERICAN INDIAN; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; ETHNIC GROUP; EUROPE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SOUTH ASIA; SPECTROPHOTOMETRY;

EID: 0029987313     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650395     Document Type: Article

References (42)

1. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Haemost 1990; 26: 207-16.
2. Auwerx J, Bouillon R, Collen D, Geboers D. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72.
3. Garcia Frade LJ, de la Calle H, Torrado MC, Lara JI, Cuellar L, Garcia A. Hypofibrinolysis associated with vasculopathy in non-insulin dependent diabetes mellitus. Thromb Res 1990; 59: 51-9.
4. Nagi DK, Jain S, Garvey S, Walji S, Yudkin JS. Defective Fibrinolysis in non-insulin-dependent diabetes mellitus relates to plasma insulin concentrations. Clin Sci 1991; 80(suppl 24): 25p.
5. Man Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic subjects. Relationship with plasma insulin. Thromb Haemost 1989; 61: 370-3.
6. Vague P, Juhan-Vague I, Chabret V, Alessi MC, Allan C. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 1989; 38: 913-5.
7. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor 1. Metabolism 1990; 39: 1044-8.
8. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentration. J Am Coll Cardiol 1987; 9: 263-8.
9. Paramo JA, Colucci M, Collen D, van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 575-6.
10. Hamsten A, Wiman D, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
11. Juhan Vague I, Alessi MC, Joly P, Thirion W, Vague P, Declerk PJ, Serradimigni A, Collen D. Plasma plasminogen activator inhibitor in angina pectoris. Influence of plasma insulin and acute phase response. Arteriosclerosis 1989; 9: 362-7.
12. Hamsten A, Walldius G, Szamosi A, de Faire U, Dahlen G, Landou C, Wiman B, Blombäck M. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-8.
13. Gray R, Yudkin JS, Patterson D. Plasminogen activator inhibitor: a risk factor for acute myocardial infarction in diabetic patients. Br Heart J 1993; 69: 228-32.
14. Potter van Loon BJ, Kluft C, Radder MA, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993; 42: 945-9.
15. Juhan Vague I, Thompson SG, Jespersen J, on behalf of the ECAT Angina Pectoris Study Group. Involvement of the haemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13: 1865-73.
16. Juhan Vague I, Vague Ph, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationship between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor-1. Diab Metab 1987; 13: 331-6.
17. Juhan Vague I, Alessi MC, Vague P. Increased plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-62.
18. Knowler WC, Bennett PH, Hamman RF, Miller M. Diabetes incidence and prevalence in Pima Indians: a 19 fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 1978; 108: 497-505.
19. Mather HM, Keen H. The Southall diabetic survey: prevalence of known diabetes in Asians and Europeans. Br Med J 1985; 291: 1081-4.
20. Mohan V, Sharp PS, Cloke HR, Burrin JM, Schumer B, Kohner EM. Serum immunoreactive insulin responses to a glucose load in Asian, Indian and European Type 2 (non-insulin-dependent) diabetic patients and control subjects. Diabetologia 1986; 29: 235-7.
21. Sharp PS, Mohan V, Levy JC, Mather HM, Kohner EM. Insulin resistance in patients of Asian, Indian and European origin with non-insulin-dependent diabetes. Horm Metab Res 1987; 19: 84-5.
22. McKeigue PM, Marmot MG, Syndercombe Court YD, Cottier DE, Rahman S, Riemersma RA. Diabetes, hyperinsulinaemia, and coronary risk factors in Bangladeshis in East London. Br Heart J 1988; 60: 390-6.
23. Nagulesparan M, Savage PJ, Knowler WC, Johnson GC, Bennett PH. Increased in vivo insulin resistance in non-diabetic Pima Indians compared with Caucasians. Diabetes 1982; 31: 952-6.
24. Lillioja S, Nyomba BL, Saad MF, Ferraro R, Castillo C, Bennett PH, Bogardus C. Exaggerated early insulin release and insulin resistance in a diabetes-prone population: a metabolic comparison of Pima Indians and Caucasians. J Clin Endocrinol Metab 1991; 73: 866-76.
25. Nelson RG, Sievers ML, Knowler WC, Swinburn BA, Pettitt DJ, Saad FM, Leibow IW, Howard BV, Bennett PH. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 1990; 81: 987-95.
26. Sievers ML. Myocardial infarction among southwestern American Indians. Ann Intern Med 1967; 67: 800-7.
27. Ingelfinger JA, Bennett PH, Liebow IM, Miller M. Coronary heart disease in the Pima Indians: Electrocardiographic findings and postmortem evidence of myocardial infarction in a population with a high prevalence of diabetes mellitus. Diabetes 1976; 25: 561-5.
28. Howard BV, Lisse JR, Knowler WC, Davis MP, Pettitt DJ, Bennett PH. Diabetes and atherosclerosis in the Pima Indians. Mt Sinai J Med (NY) 1982; 49: 169-75.
29. Marmot M, Adelstein A. Immigrant mortality in England and Wales 1970-1978. Population Trends 1985; 33: 14-7.
30. Nagi DK, Mohamed Ali V, Jain SK, Walji S, Yudkin JS. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance or non-diabetic Asians. Diab Med 1996; 13: 59-64.
31. World Health Organisation. Diabetes mellitus: Report of a WHO Study Group. Technical Report Series No 727, WHO, Geneva 1985.
32. Stein MW. D Glucose determination with Hexokinase and Glucose-6-phosphatase Dehydrogenase. In: Methods of enzymatic analysis. Bergmeyer HU, ed. Academic Press, New York, 1953, p 117.
33. Sobey WJ, Beer SF, Carrington CA, Clark PMS, Frank BH, Gray P, Luzio S, Owens DR, Schneider AE, Siddle K, Temple RC, Hales CN. Sensitive and specific two-site immunoradiometric assays to human insulin, proinsulin, 65-66 split and 32-33 split proinsulin. Biochem J 1989; 260: 535-41.
34. Mohamed-Ali V, Yudkin JS. An end-point amplified immunoenzymometric assay (IEMA) specific for human insulin. Clin Sci 1992; 82 (Suppl 27): 4P.
35. Mohamed-Ali V, Yudkin JS. Simple and highly sensitive microplate assays (IRMAs) for intact proinsulin and des 31,32 proinsulin. Diabetic Med 1993; 10(suppl 1): p67.
36. Chmielewska J, Ranby M, Wiman B. Evidence of a rapid inhibitor to tissue plasminogen activators in plasma. Thromb Res 1983; 31: 427-36.
37. Thompson SG, Kienast J, Pyke S, Haverkate F, van de Loo JCW. Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Eng J Med 1995; 332: 635-41.
38. Dawson S, Hamsten A, Wiman B, Henny A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is assoicated with altered levels of plasminogen activator inhibitor-1 activity. Arteriosclerosis and Thrombosis 1991; 11: 183-90.
39. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries S, Yudkin JS. Polymorphism in the promoter of the plasminogen activator (PAI-1) gene as a strong determinant of PAI-1 activity in non-insulin-dependent diabetes. Diabetes 1995; 44: 37-42.
40. Bahru Y, Kesteven P, Alberti KG, Walker M. Decreased plasminogen activator inhibitor-1 activity in newly diagnosed type 2 diabetic patients following dietary modification. Diabetic Med 1993; 10: 802-6.
41. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemia. Diabetic Med 1993; 10: 27-32.
42. Lillioja S, Mott D, Spraul M, Ferraro R, Foley J, Ravussin E, Knowler WC, Bennett PH, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993; 329: 1988-92.